Skip to main content

Valsartan Manufacturers To Face Fraud Claims

Valsartan Manufacturers To Face Fraud Claims

Valsartan Manufacturers To Face Fraud Claims

Introduction

Last Friday, Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey, presiding over the Valsartan multidistrict litigation (MDL), denied dismissing fraud-based claims against the manufacturers of the blood pressure drug.

According to the order dated January 29, Judge Kugler upheld claims of fraudulent misrepresentation, fraudulent concealment, and other fraud-based claims against manufacturers and dismissed them without prejudice against the wholesalers and pharmacies, stating that they were too conclusory to fulfill Rule 9(b)’s particularity requirement.

The opinion stated that the fraud claims are viable against the manufacturers as the consumers included precision and a large measure of substantiation into their allegations.

The judge said the allegations made against the manufacturers are sufficient to raise an inference of knowledge or, at the very least, recklessness and disagreed with manufacturers' argument that the consumers failed to show knowledge or scienter in their allegations.

A week ago, Judge Kugler also rejected bids from the defendants over the dismissal of warranty claims, stating that the claims are viable against the manufacturers as they marketed their products as "valsartan or valsartan‐containing, and all three sets of defendants should face certain breach of implied warranty claims.

Currently, several hundred product liability lawsuits are pending in the litigation docket, each raising similar allegations that long-term exposure to recalled valsartan drug results in stomach cancer, liver cancer, esophageal cancer, prostate cancer, pancreatic cancer, and other injuries. The lawsuits are consolidated under MDL No. 2875 in the United States District Court, District of New Jersey.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!